Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland

Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland

The emergence of a highly transmissible and a more pathogenic B.1.617.2 (delta) variant of SARS-CoV-2 has brought concern over COVID-19 vaccine efficacy and the increased risk of severe breakthrough infections. The objective of this study was to assess the frequency and the clinical characteristics...

Full description

Bibliographic Details
Main Authors: Piotr Rzymski, Monika Pazgan-Simon, Juliusz Kamerys, Anna Moniuszko-Malinowska, Katarzyna Sikorska, Joanna Wernik, Dorota Zarębska-Michaluk, Łukasz Supronowicz, Barbara Sobala-Szczygieł, Agata Skrzat-Klapaczyńska, Krzysztof Simon, Anna Piekarska, Piotr Czupryna, Małgorzata Pawłowska, Michał Brzdęk, Jerzy Jaroszewicz, Justyna Kowalska, Marcin Renke, Robert Flisiak
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Vaccines
Subjects:
breakthrough infections
COVID-19 vaccines
SARS-CoV-2
booster dose
pandemic
inflammation
Online Access:https://www.mdpi.com/2076-393X/10/4/557

Internet

https://www.mdpi.com/2076-393X/10/4/557

Similar Items